Hyperglycemia - Pipeline Review, H2 2014 st
On 31 October 2014
Summary Hyperglycemia - Pipeline Review, H2 2014, provides an overview of the Hyperglycemias therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hyperglycemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperglycemia and special features on late-stage and discontinued projects.
You can buy this Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-hyperglycemia-pipeline-review-h2-2014-126964 Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope - The report provides a snapshot of the global therapeutic landscape of Hyperglycemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperglycemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperglycemia products under development by companies and universities/research institutes based on information derived from company and industryspecific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperglycemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products
Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
- Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyperglycemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyperglycemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Table of Content List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hyperglycemia Overview 6 Therapeutics Development 7 Pipeline Products for Hyperglycemia - Overview 7 Pipeline Products for Hyperglycemia - Comparative Analysis 8 Hyperglycemia - Therapeutics under Development by Companies 9 Hyperglycemia - Therapeutics under Investigation by Universities/Institutes 10 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Hyperglycemia - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Hyperglycemia - Products under Development by Companies 14 Hyperglycemia - Products under Investigation by Universities/Institutes 15 Hyperglycemia - Companies Involved in Therapeutics Development 16 Kissei Pharmaceutical Co., Ltd. 16 Mitsubishi Tanabe Pharma Corporation 17 PhaseBio Pharmaceuticals, Inc. 18 Hyperglycemia - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 PE-0139 - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 KR-62980 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ZLN-005 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules to Inhibit PEPCK for Diabetes and Hyperglycemia - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules to Inhibit Prokineticin Receptor for Metabolic Disorders - Drug Profile 35 Product Description 35 Mechanism of Action 35 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
R&D Progress 35 55-P-0251 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Inhibit DPP-IV for Hyperglycemia - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 FGH-10019 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Antisense Oligonucleotides to Target ABHD6 for Gastrointestinal and Metabolic Disorders Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecules to Antagonize PST Receptor for Dysglycemic States - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Hyperglycemia - Recent Pipeline Updates 42 Hyperglycemia - Dormant Projects 43 Hyperglycemia - Product Development Milestones 44 Featured News & Press Releases 44 Dec 06, 2011: Study Shows Combination Insulin Degludec/Insulin Aspart Significantly Reduced Hypoglycaemia In Type 1 And Type 2 Diabetes Patients 44 Nov 15, 2011: PhaseBio Announces Positive Results From Phase I/IIa Trial Of Glymera For Treatment Of Hyperglycemia In Patients With Type 2 Diabetes 44 Jul 21, 2011: Kissei Pharma Launches Glubes In Japan For Treatment Of Type 2 Diabetes 45 Appendix 46 Methodology 46 Coverage 46 Secondary Research 46 Primary Research 46 Expert Panel Validation 46 Contact Us 47 Disclaimer 47 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
List Of Tables Number of Products under Development for Hyperglycemia, H2 2014 7 Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Hyperglycemia - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2014 16 Hyperglycemia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 17 Hyperglycemia - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 18 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Stage and Target, H2 2014 21 Number of Products by Stage and Mechanism of Action, H2 2014 23 Number of Products by Stage and Route of Administration, H2 2014 25 Number of Products by Stage and Molecule Type, H2 2014 27 Hyperglycemia Therapeutics - Recent Pipeline Updates, H2 2014 42 Hyperglycemia - Dormant Projects, H2 2014 43 List Of Figures Number of Products under Development for Hyperglycemia, H2 2014 7 Number of Products under Development for Hyperglycemia - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Number of Products under Investigation by Universities/Institutes, H2 2014 10 Comparative Analysis by Early Stage Products, H2 2014 13 Assessment by Monotherapy Products, H2 2014 19 Number of Products by Top 10 Target, H2 2014 20 Number of Products by Stage and Top 10 Target, H2 2014 21 Number of Products by Top 10 Mechanism of Action, H2 2014 22 Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 23 Number of Products by Top 10 Route of Administration, H2 2014 24 Number of Products by Stage and Top 10 Route of Administration, H2 2014 25 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Number of Products by Top 10 Molecule Type, H2 2014 26 Number of Products by Stage and Top 10 Molecule Type, H2 2014 27
Report Price: Licence Type
Price
$ 2000
Site Licence
$ 4000
Enterprise Wide Licence
$ 6000
Related Reports: Callaghan Innovation Research Ltd. – Strategic SWOT Analysis Review Vital Living, Inc. (VTLV) – Strategic SWOT Analysis Review Nexgen Pharma, Inc. – Strategic SWOT Analysis Review EBEWE Pharma Ges.m.b.H. Nfg.KG – Strategic SWOT Analysis Review Hoag Memorial Hospital Presbyterian – Strategic SWOT Analysis Review Promethean Corporation – Strategic SWOT Analysis Review Millenia Hope Inc. (MLHI) – Strategic SWOT Analysis Review Glory Biotech Co., Ltd. (4187) – Financial and Strategic SWOT Analysis Review Audiotech Healthcare Corporation – Strategic SWOT Analysis Review UMN Pharma Inc. (4584) – Financial and Strategic SWOT Analysis Review
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Hyperglycemia - Pipeline Review, H2 2014 http://www.jsbmarketresearch.com/healthcare-medical/r-hyperglycemiapipeline-review-h2-2014-126964
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/